Skip to main content
Clinical Trials/NCT02161484
NCT02161484
Terminated
N/A

A Prospective, Randomized, Blinded, Controlled Study Evaluating the Efficacy of Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

Rita Merman1 site in 1 country10 target enrollmentJanuary 2014

Overview

Phase
N/A
Intervention
Continuous Lumbar Plexus Block
Conditions
Osteoarthritis of Hip
Sponsor
Rita Merman
Enrollment
10
Locations
1
Primary Endpoint
Numeric Rating Scale (NRS) Pain Assessment
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this research study is to evaluate the analgesic efficacy of adding a single shot parasacral (sciatic) nerve block to a continuous lumbar plexus block in patients undergoing total hip replacement.

Detailed Description

This prospective study is intended to assess the efficacy of placing a parasacral (sciatic) nerve block in addition to a lumbar plexus block for postoperative analgesia following total hip arthroplasty. Although the placement of a lumbar plexus block alone has become accepted as the standard of care at UPMC for postoperative analgesia following total hip arthroplasty, the addition of a parasacral (sciatic) nerve block may provide the advantage of blocking the superior gluteal nerve and nerve to the quadratus femoris which both supply small articular sensory branches to the posterior hip capsule.

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
June 17, 2014
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Rita Merman
Responsible Party
Sponsor Investigator
Principal Investigator

Rita Merman

MD

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Subject has signed and dated an Informed Consent Form.
  • Subject is classified as a ASA (American Society of Anesthesiologists) status I-III
  • Subject is age 18- 75 years old.
  • Subject is having primary total hip arthroplasty
  • No contraindication to peripheral nerve catheter ( local infection or hypocoagulable state)
  • Patient willing to receive spinal anesthesia as operative anesthesia
  • No known drug allergies to study medications
  • Patients not expected to receive therapeutic anticoagulation in the postoperative period.

Exclusion Criteria

  • Subject inability to provide adequate informed consent.
  • Age younger than 18 years or older than 75 years
  • Any contraindication to the placement of lumbar plexus catheter, including local infection, hypocoagulable state.
  • ASA (American Society of Anesthesiologists) physical status of IV or greater
  • Any chronic painful conditions
  • Preoperative opioid use
  • Coagulation abnormalities or patients who are expected to be on therapeutic anticoagulants postoperatively

Arms & Interventions

Continuous Lumbar Plexus Block with Parasacral Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.

Intervention: Continuous Lumbar Plexus Block

Continuous Lumbar Plexus Block with Parasacral Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.

Intervention: Parasacral Nerve Block

Continuous Lumbar Plexus Block with Parasacral Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.

Intervention: Ropivacine 0.2%

Continuous Lumbar Plexus Block with Parasacral Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.

Intervention: Bupivacaine 0.0625%

Lumbar Plexus Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. No sham/placebo parasacral (sciatic) blocks will be performed in this group.

Intervention: Continuous Lumbar Plexus Block

Lumbar Plexus Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. No sham/placebo parasacral (sciatic) blocks will be performed in this group.

Intervention: Ropivacine 0.2%

Lumbar Plexus Nerve Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn. No sham/placebo parasacral (sciatic) blocks will be performed in this group.

Intervention: Bupivacaine 0.0625%

Outcomes

Primary Outcomes

Numeric Rating Scale (NRS) Pain Assessment

Time Frame: 48 hours after the start of surgery

Postoperative pain assessments using a 11-point numerical rating during physical therapy and at rest. This pain scale ranges from 0, being no pain at all, up to 10 being the worst pain ever experience.

Secondary Outcomes

  • Amount of Oxycodone for the First 48 h Post Operatively(48 hours after the start of the surgery)
  • Total Dilaudid or Opiate Equivalent Consumed (mg) Over 48 Hours Post Operatively(48 hours after the start of the surgery)
  • Number of Nerve Block Boluses (Bupivacaine) Administered by the Nurse Post Operatively(48 hours after the start of the surgery)
  • Total Amount of Local Anesthetic in 48 Hours Post Operatively(48 hours after the start of the surgery)
  • Number of Rescue Boluses Administered by Nurse (IV Dilaudid) Post Operatively(48 hours after the start of the surgery)

Study Sites (1)

Loading locations...

Similar Trials